The MCV4 vaccine, also known as the meningococcal conjugate vaccine, protects against four types (serogroups A, C, W, and Y) of the bacteria that cause meningococcal disease. This disease is a serious bacterial infection that affects the brain and spinal cord and can cause meningitis, which can be life- threatening. Key points about the MCV4 vaccine:
- It is a quadrivalent vaccine targeting serogroups A, C, W-135, and Y.
- Available forms in the US include Menactra and Menveo.
- It is approved for people from 2 through 55 years of age, with some approvals for younger children.
- Recommended for routine vaccination in adolescents, typically given as two doses: the first dose at 11 or 12 years old and a booster at age 16.
- It is often required for students entering 11th grade or college freshmen living in dorms.
- It is a conjugate vaccine that provides longer-lasting protection compared to older polysaccharide vaccines.
- Side effects can include redness or pain at the injection site and sometimes fever, typically resolving within 1-2 days.
The vaccine helps lower the risk of meningitis outbreaks and protects against severe complications of meningococcal disease.
